All In Biotech

Drug Trial Radar · NCT06933043

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.

A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous NAV-240 in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

May 20, 2025

Primary completion

Nov 20, 2025

Study completion Nov 20, 2025

Sponsor

Lead sponsor
Navigator Medicines, Inc.Industry
Sponsor type
Industry
Collaborators
Southern Star Research
First posted
Apr 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess initial safety/tolerability of multiple doses of drug NAV-240. It will also learn about the profile and immunogenicity of drug NAV-240. The main question it aims to answer is: • What medical problems do participants have when taking multiple doses of drug NAV-240? Researchers will compare drug NAV-240 to a placebo (a look-alike substance that contains no drug) to see if any medical problems participants have differ between those taking drug NAV-240 and those taking placebo.

Conditions

  • Healthy Volunteers

Interventions

  • NAV-240Drug

    Three doses of intravenous (IV) low dose, medium dose or high dose NAV-240 will be administered to participants.

  • PlaceboDrug

    Three doses of matching placebo will be administered to participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence and severity of any treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Through 6 weeks after last dose of study drug.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.